# OnCo record egfr-mutant-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/egfr-mutant-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "egfr-mutant-nsclc" ;
  schema:name "EGFR-mutated non-small-cell lung cancer"@en ;
  schema:alternateName "EGFR-mutant lung cancer"@en, "EGFR-positive NSCLC"@en, "EGFR exon 19 deletion lung cancer"@en, "EGFR L858R lung cancer"@en, "EGFR exon 20 insertion lung cancer"@en ;
  schema:description "EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease."@en ;
  schema:url <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor> ;
  schema:citation <https://en.wikipedia.org/wiki/Epidermal_growth_factor_receptor>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/radiosurgery-srs/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/afatinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/furmonertinib/>, <https://onco.cc/drugs/mobocertinib/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/drugs/patritumab-deruxtecan/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/johnson-johnson/>, <https://onco.cc/companies/yuhan/>, <https://onco.cc/companies/dizal/>, <https://onco.cc/companies/daiichi-sankyo/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/leptomeningeal-disease/> ;
  onco:trials <https://onco.cc/trials/flaura/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/trials/nct04538664/>, <https://onco.cc/trials/nct03974022/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/trials/laura/>, <https://onco.cc/trials/tropion-lung05/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/trials/gefitinib-chemo-tmh/> ;
  onco:people <https://onco.cc/people/thomas-lynch/>, <https://onco.cc/people/daniel-haber/>, <https://onco.cc/people/tony-mok/>, <https://onco.cc/people/jean-charles-soria/>, <https://onco.cc/people/suresh-ramalingam/>, <https://onco.cc/people/pasi-janne/>, <https://onco.cc/people/wu-yi-long/>, <https://onco.cc/people/roy-herbst/>, <https://onco.cc/people/cho-byoung-chul/>, <https://onco.cc/people/lecia-sequist/>, <https://onco.cc/people/david-planchard/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-flaura-nejm-2018/>, <https://onco.cc/key-papers/paper-mariposa-nejm-2024/>, <https://onco.cc/key-papers/paper-adaura-nejm-2020/> ;
  onco:pipeline <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/trials/herthena-lung02/>, <https://onco.cc/drugs/zipalertinib/>, <https://onco.cc/trials/nct05973773/>, <https://onco.cc/drugs/furmonertinib/>, <https://onco.cc/drugs/befotertinib/>, <https://onco.cc/drugs/silevertinib/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/ideas/idea-bio1-ctdna-adaptive-tki/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/trials/flaura/>, <https://onco.cc/trials/flaura2/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/lazertinib/>, <https://onco.cc/pairings/amivantamab-plus-lazertinib/>, <https://onco.cc/trials/mariposa/>, <https://onco.cc/terms/egfr-exon19-l858r/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/trials/nct04538664/>, <https://onco.cc/drugs/sunvozertinib/>, <https://onco.cc/trials/nct03974022/>, <https://onco.cc/terms/egfr-exon20-insertion/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/trials/tropion-lung05/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/c797s/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/trials/adaura/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/trials/laura/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/technologies/radiosurgery-srs/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/leptomeningeal-disease/> .